Cilnidipine antihypertensive efficacy, pleiotropic benefits and experiences by cardiologists: findings from a digital questionnaire-based study

Pavan S. Agrawal; Pratibha N. Karande; Kunal J. Khobragade

doi:10.18203/2349-3933.ijam20260390

Authors

Pavan S. Agrawal Department of Cardiology, Radiant Super Speciality Hospital, Amravati, Maharashtra, India
Pratibha N. Karande Department of Medical Affairs, Mankind Pharma Ltd., Navi Mumbai, Maharashtra, India
Kunal J. Khobragade Department of Medical Affairs, Mankind Pharma Ltd., Navi Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20260390

Keywords:

Cilnidipine, Hypertension, Calcium channel blocker

Abstract

Background: Cilnidipine, a fourth-generation calcium channel blocker with dual L- and N-type action, offers distinct benefits in hypertension, though varied cardiologist awareness and prescribing may limit optimal use.

Methods: A cross-sectional survey was conducted among 416 practicing cardiologists across India between 17 April and 15 July 2025 to assess knowledge, perceptions, and prescribing preferences for cilnidipine in essential hypertension. A validated 20-item self-administered multiple-choice questionnaire captured mechanistic understanding and clinical perspectives following e-consent. Items addressed comparative advantages over other calcium channel blockers, effects on target organs, therapeutic applications (including combinations and patient subgroups), and metabolic benefits in metabolic syndrome. Responses were collected electronically and analyzed using descriptive statistics to summarize awareness and prescribing trends.

Results: Most cardiologists (85.1%) identified cilnidipine’s dual L- and N-type blockade as its key differentiator from conventional CCBs. Over half recognized its superior nocturnal BP control (56.3%), reduced BP variability via autonomic stabilization (52.6%), and lowering of mean arterial pressure without reflex tachycardia (54.6%). A substantial proportion (64.2%) acknowledged reno-protective benefits over amlodipine, while 55.8% favored its use in elderly and resistant hypertensive patients. Notably, 61.0% recognized improved insulin sensitivity in metabolic syndrome. However, knowledge gaps remained regarding its effects on the RAAS and endothelial function.

Conclusions: The survey reveals strong cardiologist awareness of cilnidipine’s sympatholytic, reno-protective, and hemodynamic benefits, alongside partial misconceptions regarding RAAS and endothelial effects. These findings underscore the need for ongoing clinical education and support cilnidipine’s role as a well-tolerated, organ-protective antihypertensive.

Metrics

Metrics Loading ...

References

Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-37. DOI: https://doi.org/10.1038/s41581-019-0244-2

Jones KE, Hayden SL, Meyer HR, Sandoz JL, Arata WH, Dufrene K, et al. The evolving role of calcium channel blockers in hypertension management: pharmacological and clinical considerations. Curr Issues Mol Biol. 2024;46(7):6315-27. DOI: https://doi.org/10.3390/cimb46070377

Chandra KS, Ramesh G. The fourth-generation Calcium channel blocker: cilnidipine. Indian Heart J. 2013;65(6):691-5. DOI: https://doi.org/10.1016/j.ihj.2013.11.001

Mohanty M, Tripathy K, Srakar S, Srivastava V. Evaluation of safety and tolerability of amlodipine and cilnidipine - a comparative study. Sch J App Med Sci. 2016;4(8):2884-94.

Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279(23):1903. DOI: https://doi.org/10.1001/jama.279.23.1903

Vukadinović D, Scholz SS, Messerli FH, Weber MA, Williams B, Böhm M, et al. Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. Journal of Hypertension. 2019;37(10):2093-103. DOI: https://doi.org/10.1097/HJH.0000000000002145

Ozawa Y, Hayashi K, Kobori H. New Generation Calcium Channel Blockers in Hypertensive Treatment. CHYR. 2006;2(2):103-11. DOI: https://doi.org/10.2174/157340206776877370

Chakraborty RN, Langade D, More S, Revandlkar V, Birla A. Efficacy of Cilnidipine (L/N-type Calcium Channel Blocker) in Treatment of Hypertension: A Meta-Analysis of Randomized and Non-randomized Controlled Trials. Cureus. 2021. DOI: https://doi.org/10.7759/cureus.19822

Adake P, Somashekar H, Mohammed Rafeeq P, Umar D, Basheer B, Baroudi K. Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study. J Adv Pharm Technol Res. 2015;6(2):81. DOI: https://doi.org/10.4103/2231-4040.154543

Joo HJ, Oh S, Hong SJ, Yu CW, Kim YH, Kim EJ. COMPARATIVE EFFICACY OF AMLODIPINE and lercanidipine in the prevention of major adverse cardiovascular events in hypertensive patients. J Hypertens. 2024;42(1):258. DOI: https://doi.org/10.1097/01.hjh.0001022148.28547.f7

Shete MM. Cilnidipine: Next Generation Calcium Channel Blocker. J Assoc Cardiologists India. 2016;64(4):95-9.

Soeki T, Kitani M, Kusunose K, Yagi S, Taketani Y, Koshiba K, et al. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients. Hypertens Res. 2012 Nov;35(11):1058-62. DOI: https://doi.org/10.1038/hr.2012.96

Nagai H, Minatoguchi S, Chen XH, Wang N, Arai M, Uno Y, et al. Cilnidipine, an N+L-Type Dihydropyridine Ca Channel Blocker, Suppresses the Occurrence of Ischemia/Reperfusion Arrhythmia in a Rabbit Model of Myocardial Infarction. Hypertens Res. 2005;28(4):361-8. DOI: https://doi.org/10.1291/hypres.28.361

Jarari N, Rao N, Peela JR, Ellafi KA, Shakila S, Said AR, et al. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens. 2015;22:7. DOI: https://doi.org/10.1186/s40885-016-0042-0

Shete M, Saxena A, Nakrani A, Shah C, Bhojwani H, Jiwane D. Assessing cilnidipine and its combination usage in Indian settings: a knowledge, attitude, and practice survey. Int J Adv Med. 2024;11(6):559-65. DOI: https://doi.org/10.18203/2349-3933.ijam20243058

Kishi T, Hirooka Y, Konno S, Sunagawa K. Cilnidipine Inhibits the Sympathetic Nerve Activity and Improves Baroreflex Sensitivity in Patients with Hypertension. Clinical and Experimental Hypertension. 2009;31(3):241–9. DOI: https://doi.org/10.1080/10641960902822492

Kadian R, Nanda A. A Comprehensive Insight on Pharmacological Properties of Cilnidipine: AFourth-generation Calcium Channel Blocker. CHAMC. 2024;22(1):40-50. DOI: https://doi.org/10.2174/1871525721666230224111518

Hoshide S, Kario K, Ishikawa J, Eguchi K, Shimada K. Comparison of the Effects of Cilnidipine and Amldipine on Ambulatory Blood Pressure. Hypertens Res. 2005;28(12):1003-8. DOI: https://doi.org/10.1291/hypres.28.1003

Pathapati RM. An Open Label Parallel Group Study to Assess the Effects of Amlodipine and Cilnidipine on Pulse Wave Velocity and Augmentation Pressures in Mild to Moderate Essential Hypertensive Patients. JCDR. 2015;9(11). DOI: https://doi.org/10.7860/JCDR/2015/12702.6754

Mehta K, Tiwaskar M, Kasture P. Cilnidipine, a Dual L/N-type Ca. JAPI. 2024;72(4):54-8. DOI: https://doi.org/10.59556/japi.72.0516

Kojima S, Shida M, Yokoyama H. Comparison between Cilnidipine and Amlodipine Besilate with Respect to Proteinuria in Hypertensive Patients with Renal Diseases. Hypertens Res. 2004;27(6):379-85. DOI: https://doi.org/10.1291/hypres.27.379

Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, et al. Different Effects of L/N-Type and L-Type Calcium Channel Blockers on the Renin-Angiotensin-Aldosterone System in SHR/Izm. Am J Nephrol. 2009;30(2):155-61. DOI: https://doi.org/10.1159/000210396

Nap A, Mathy M, Balt JC, Pfaffendorf M, Van Zwieten PA. The evaluation of the N‐type channel blocking properties of cilnidipine and other voltage‐dependent calcium antagonists. Fund Clin Pharma. 2004 June;18(3):309-19. DOI: https://doi.org/10.1111/j.1472-8206.2004.00236.x

Fan L, Yang Q, Xiao XQ, Grove KL, Huang Y, Chen ZW, et al. Dual actions of cilnidipine in human internal thoracic artery: Inhibition of calcium channels and enhancement of endothelial nitric oxide synthase. J Thorac Cardiovasc Surg. 2011;141(4):1063-9. DOI: https://doi.org/10.1016/j.jtcvs.2010.01.048

Vivek G, Tumkur A, Naha K, Raj A, Bairy K, Shetty R. Excellent tolerance to cilnidipine in hypertensives with amlodipine - induced edema. North Am J Med Sci. 2013;5(1):47. DOI: https://doi.org/10.4103/1947-2714.106203

Nagahama S, Norimatsu T, Maki T, Yasuda M, Tanaka S. The Effect of Combination Therapy with an L/N-Type Ca2+ Channel Blocker, Cilnidipine, and an Angiotensin II Receptor Blocker on the Blood Pressure and Heart Rate in Japanese Hypertensive Patients: An Observational Study Conducted in Japan. Hypertens Res. 2007;30(9):815-22. DOI: https://doi.org/10.1291/hypres.30.815

Tomiyama H, Kimura Y, Kuwabara Y, Maruyama C, Yoshida Y, Kuwata S, et al. Cilnidipine More Highly Attenuates Cold Pressor Stress-Induced Platelet Activation in Hypertension than Does Amlodipine. Hypertens Res. 2001;24(6):679-84. DOI: https://doi.org/10.1291/hypres.24.679